Post by GSK on X
GSK@GSK
X#News for #investors & #media: Japan has become the first country to approve a new therapy for people living with chronic hepatitis B (CHB), marking an important milestone in liver disease innovation.
CHB remains a leading cause of liver cancer worldwide. This approval reflects
60 likes5 repliesPosted Aug 24, 2026